[Increased thrombolysis and decreased platelet aggregation with an anti-GPIIb/IIIa antibody urokinase hybrid molecule (7E3-UK)].
Bode
C
C
Medizinische Klinik III-Kardiologie, Universität Heidelberg.
Nordt
T
T
Freitag
M
M
Ruef
J
J
Kaltenmeier
M
M
Meinhardt
G
G
Kübler
W
W
Haber
E
E
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D005341:Fibrinolysin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D010958:Plasminogen / Q000378:metabolism; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D015912:Thrombolytic Therapy / Q000379:methods*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D010980:Platelet Membrane Glycoproteins; D010958:Plasminogen; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator
Verstärkte Thrombolyse und verminderte Thrombozytenaggregation durch ein anti-GPIIb/IIIa-Antikörper Urokinase Hybridmolekül (7E3-UK).